HDFC Securities' research report on Emami
Emami delivered 1% YoY revenue growth, with organic domestic revenue declining by ~2%. Growth pressure was witnessed across the brands, with Boroplus/Navratana/Kesh King/Healthcare/F&H clocking YoY growth of -3/-6/- 1/+2/-1%. International business too witnessed growth deceleration, registering 7% growth (20% in 9M). GM remained under pressure, contracting by 150/70bps YoY/QoQ to 66%. Emami has accelerated upfront expenses (employee hiring, distribution, etc.); thus, the EBITDA margin contracted by >500bps YoY to 30%. EBITDA declined by 14% YoY (HSIE -15%). Emami is trying to add new growth levers (acquired Dermicool and Helios Lifestyle) along with expanding team width. However, we remain cautious about the core business growth, given the limited scope to add new consumers in niche categories.
Outlook
Further, we believe that Emami has already peaked at its current margin level, sustaining which would be difficult (also seen in the last 3-4 quarters). We value the stock at 25x P/E on Dec-24E EPS to derive a TP of INR 450. Maintain REDUCE.
For all recommendations report, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.